Posters and Publications

This page is intended to provide scientific information to research and healthcare professionals. Evofem Biosciences’ first commercial product was recently approved by the Food and Drug Administration. The Company is also advancing EVO100 into Phase 3 clinical trials for the prevention of urogenital transmission of both Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women. EVO100 has not been approved by the Food and Drug Administration or any other regulatory agency.

Author(s)

Publication

Title

Date

Chappell, et al. Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecology (ACOG) Perfect-Use Pregnancy Rates with Vaginal pH Regulator: Efficacy Results from AMPOWER October 2020
Thomas, et al. Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecology (ACOG) Sexual Satisfaction With Vaginal pH Regulator: Results From The AMPOWER Clinical Trial October  2020
Maximos, et al. Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecology (ACOG) Genitourinary Side Effects With Vaginal pH Regulator: Results From AMPOWER October 2020
Thomas, et al. American Society for Reproductive Medicine (ASRM) Sexual Satisfaction With a Vaginal pH Regulator (EVO100): Results From the AMPREVENCE Clinical Trial October 2020
Thomas, et al. American Society for Reproductive Medicine (ASRM) Characterization of Women According to Their Sexual Satisfaction After Treatment With the Novel Vaginal pH Regulator (VPR™) During the AMPOWER Study October 2020
Howard, et al. Nurse Practitioners in Women’s Health (NPWH) A Comparison of Women Who Completed or Discontinued the AMPOWER Study, a Phase 3 Contraceptive Trial for Vaginal pH Regulator October 2020
Mena, et al. Society for Family Planning (SFP) Impact of Product Adherence and Condom Use on Rates of Urogenital Re-infection with Chlamydia Trachomatis or Neisseria Gonorrhoeae in the AMPREVENCE Phase 2b/3 Clinical Trial October 2020
Maximos, et al. Society for Family Planning (SFP) Characterization of Women According to Pregnancy Status Following Treatment with VPR During the AMPOWER Study October 2020
Chappell, et al. STD Prevention Conference (STDC) Efficacy and Safety of Vaginal pH Regulator for Prevention of Chlamydia and Gonorrhea September 2020
Thomas, et al. Contraception X A Novel Vaginal pH Regulator: Results From The Phase 3 AMPOWER Contraception Clinical Trial April 2020
Cason, et al. Nurse Practitioners in Women’s Health (NPWH) Healthcare Conference Efficacy and Safety of a Vaginal pH Regulator: Results from the Phase 3, AMPOWER Clinical Trial Oct. 2019
Thomas, et al. American Society of Reproductive Medicine (ASRM) Women’s Satisfaction with the Vaginal pH Regulator (VPRTM): Results From the Phase 3 AMPOWER Trial Oct. 2019
Culwell K, et al. Fertility and Sterility A randomized, placebo-controlled pilot study to determine the effect and duration of Acidfrom gel (Amphora) on vaginal pH Oct. 2017
Friend D 2nd International Conference on Reproductive Health Amphora vaginal gel: An on-demand contraceptive with anti-STI (MPT) potential Dec. 2016
Thomas M, et al. Contraception Journal Gynecologic infections and colposcopy fidings from a phase 3 efficacy and safety study of a contracpetive vaginal gel compared with nonoxynol-9 Oct. 2016
Barnhard K, et al. Obstetrics & Gynecology Contraceptive efficacy, safety, and acceptability of Amphora (an acid-buffering vaginal gel) and Conceptrol May 2016
Bayer L, et al. Contraception Journal ACIDFORM: a review of the evidence July 2014

Evofem assumes no responsibility for the accuracy of any information or data contained on any third party website.  Evofem has not independently verified the accuracy of such information or data, and there can be no assurance as to the accuracy of any such information or data.  Links to this information and data are provided for informational purposes only.